The transaction closure is anticipated in early 2026, contingent on regulatory approvals and other customary conditions.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

George’s Donuts & Merriment is the kind of spot locals line up outside on the weekend, where you can order a flight of “fried-to-order” sugar-dusted doughnut holes served with Valrhona chocolate fudge ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

If you are wondering whether Hims & Hers Health is still a smart buy after its big run, you are not alone. This stock has quickly moved from a niche telehealth play to one of the market's more talked ...

CEO Andrew Dudum stated the company's strategy is "expanding reach, deepening engagement and transforming how people experience health care," emphasizing that "scale doesn't just make us bigger, it ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...